Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Trubicka, Joanna ^a   Grabowska Kłujszo, Ewa ^a   Suchy, Janina ^a   Masojć, Bartłomiej ^a   Serrano Fernandez, Pablo ^a   Kurzawski, Grzegorz ^a   Cybulski, Cezary ^a   Górski, Bohdan ^a   Huzarski, Tomasz ^a   Byrski, Tomasz ^a   Gronwald, Jacek ^a   Złowocka, Elzbieta ^a   Kładny, Józef ^a   Banaszkiewicz, Zbigniew ^b   Wiśniowski, Rafał ^c   Kowalska, Elzbieta ^a   Lubinski, Jan ^a   Scott, Rodney J ^d,e  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c Regional Oncology Hospital   (Poland)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1B1; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450; DNA;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE CARRIER; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLAND; SINGLE NUCLEOTIDE POLYMORPHISM; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 77955382112     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-420     Document Type: Article

References (17)

1. Spink DC, Hayes CL, Young NR, et al. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 beta-estradiol 4-hydroxylase. J Steroid Biochem Mol Biol 1994, 51:251-8. 10.1016/0960-0760(94)90037-X, 7826886.
2. Landi MT, Bergen AW, Baccarelli A, et al. CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy. Toxicology 2005, 207:191-202. 10.1016/j.tox.2004.08.021, 15596250.
3. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004, 5:211-24. 10.2174/1389200043335621, 15180491.
4. Bailey LR, Roodi N, Dupont WD, Parl FF, et al. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998, 58:5038-41.
5. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999, 20:1607-13. 10.1093/carcin/20.8.1607, 10426814.
6. Chakravarti D, Mailander PC, Li KM, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 2001, 20:7945-53. 10.1038/sj.onc.1204969, 11753677.
7. Shimada T, Hayes CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996, 56:2979-84.
8. Hanna IH, Dawling S, Roodi N, et al. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000, 60:3440-4.
9. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215. 10.1093/nar/16.3.1215, 334765, 3344216.
10. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002, 70:425-34. 10.1086/338688, 384917, 11791212.
11. Bethke L, Webb W, Sellick, et al. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP17A1, CYP19A1 and colorectal cancer risk.
12. Landi S, Gemignani F, Moreno V, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 2005, 15:535-46. 10.1097/01.fpc.0000165904.48994.3d, 16006997.
13. Aklillu E, Øvrebø S, Botnen IV, et al. Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. Cancer Res 2005, 65:5105-11. 10.1158/0008-5472.CAN-05-0113, 15958554.
14. Chang BL, Zheng HL, Isaacs SD, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 2003, 89:1524-9. 10.1038/sj.bjc.6601288, 2394327, 14562027.
15. Cicek MS, Liu X, Casey G, Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2005, 14:2173-7. 10.1158/1055-9965.EPI-05-0215, 16172228.
16. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000, 10:761-6. 10.1097/00008571-200012000-00001, 11221602.
17. Shimada T, Gilliam EM, Oda Y, et al. Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7, 8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. Chem Res Toxicol 1999, 12:623-9. 10.1021/tx990028s, 10409402.